LETTERS TO THE EDITOR

Multimodal Treatment of Clinical Non-Small Cell N2 Bronchogenic Carcinoma. What Is the Answer?

To the editor: Ten years ago, we asked what the question was and now it seems that there is an answer. The last meeting of the American Society of Clinical Oncology (May 2005) saw the presentation of the final reports of 2 randomized clinical trials where the researchers had asked whether or not combining induction chemoradiotherapy or chemotherapy with surgery improved 5-year survival. The answer provided by both clinical trials, one in the United States of America and the other in Europe, is that surgery does not improve survival. Therefore, the best available evidence (repeated randomized trials) does not indicate that surgery should be part of multimodal treatment in non-small cell bronchogenic carcinoma clearly shown to be cN2 by cytology and histology.

Later analyses of both trials, however, indicate that certain factors, taken individually for each patient, may recommend surgery in this clinical situation. One important factor is an yN0 classification (N0 following induction treatment). We have therefore changed our question. We now ask which strategy makes it possible to choose the best possible methods to ensure category yN0. This debate has only just begun.

A. López-Encuentra,* J.L. Martín de Nicolás,* L. Paz-Ares,* and A. Bartolomé,* for the Bronchogenic Carcinoma Cooperative Group of the Hospital Universitario 12 de Octubre de Madrid

*Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, Spain.
*Servicio de Cirugía de Tórax, Hospital Universitario 12 de Octubre, Madrid, Spain.
*Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, Spain.
*Servicio de Oncología Radioterapéutica, Hospital Universitario 12 de Octubre, Madrid, Spain.